Effect of tacrolimus on the results of living related kidney donor transplantation
- Authors: Goriaĭnov VA1, Kaabak MM1, Babenko NN1, Morozova MM1, Agureeva LI1, Panin VV1, Platova EN1, Vinnitskiĭ LI1, Vorob'eva NT1
-
Affiliations:
- ФГБУ "Российский научный центр хирургии им. акад. Б.В. Петровского" РАМН, Москва
- Issue: Vol 86, No 6 (2014)
- Pages: 70-73
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31512
- ID: 31512
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
V A Goriaĭnov
ФГБУ "Российский научный центр хирургии им. акад. Б.В. Петровского" РАМН, Москва
Email: vik-kid@mail.ru
M M Kaabak
ФГБУ "Российский научный центр хирургии им. акад. Б.В. Петровского" РАМН, Москва
N N Babenko
ФГБУ "Российский научный центр хирургии им. акад. Б.В. Петровского" РАМН, Москва
M M Morozova
ФГБУ "Российский научный центр хирургии им. акад. Б.В. Петровского" РАМН, Москва
L I Agureeva
ФГБУ "Российский научный центр хирургии им. акад. Б.В. Петровского" РАМН, Москва
V V Panin
ФГБУ "Российский научный центр хирургии им. акад. Б.В. Петровского" РАМН, Москва
E N Platova
ФГБУ "Российский научный центр хирургии им. акад. Б.В. Петровского" РАМН, Москва
L I Vinnitskiĭ
ФГБУ "Российский научный центр хирургии им. акад. Б.В. Петровского" РАМН, Москва
N T Vorob'eva
ФГБУ "Российский научный центр хирургии им. акад. Б.В. Петровского" РАМН, Москва
References
- Fitzsimmons W.E., Bekersky I., Dressier D.R. et al. Demographic considerations in Tacrolimus pharmacokinetics. Transplant Proc 1998; 30: 1359-1364.
- Robles-Piedras M.L., Gonsales-Lopez E.H. Tacrolimus levels in adults patients with renal transplants. Proc West Pharmacol Soc 2009; 52: 33-34.
- Han D.J., Park J.B. A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release Tacrolimus (FK-506E)-based immunosuppression regimen. Transplant Proc 2012; 44: 115-117.
- Kramer B.K., Charpantier B., Backman L. et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase Ш study. Am J Transplant 2010; 10: 2632-2643.
- Hougardy J.M., Broeders N., Klanda M. et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation 2011; 91: 566-569.
- Carcas-Sansuan A.J., Espinosa-Roman L., Almeda-Paulo G.N. et al. Conversion from Prograf to Advagraf in stable paediatric renal transplant patients and 1-year follow-up. Pediatr Nephrol 2014; 29: 117-123.
- Crespo M., Mir M., Marin M. et al. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. Transplant Proc 2009; 41: (6): 2115-2117
- Halloway R., Steinberg S., Krall K. et al. Two years postconversion from a Prograf-based regimen to once-daily Tacrolimus extended-release formulation in stable kidney-transplant recipients. Transplantation 2007; 83 (12): 1648-1651.
- De Jonge H., Kuypers D.R., Verbeke K. et al. Reduced C0 concentrations and increased dose requirement in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 2010; 90 (5): 523-529.
- Butler J.A., Roderick P., Mulee M. et al. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systemic review. Transplantation 2004; 77 (5): 769-776.